NCI is Participating in PA-12-271, Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01)

Notice Number: NOT-CA-12-015

Release Date: September 6, 2012

National Cancer Institute (NCI)

This Notice is to inform potential applicants that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has joined PA-12-271, entitled Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01).

Part 1: Overview Information

Components of Participating Organizations

The Components of Participating Organizations section of PA-12-271 is hereby revised to include the NCI:

National Institute on Aging (NIA)
National Cancer Institute (NCI)

Catalog of Domestic Assistance (CDFA) Number

93.393

Part 2: Full Text of Announcement

Section I. Funding Opportunity Description

The Funding Opportunity Description of PA-12-271 is hereby revised to state that the NCI is especially interested in studies that address relevant research questions presented in the funding opportunity announcement (FOA) that also pertain to mechanisms of action of how metformin may modify cancer risk or cancer-related mortality. Such studies may involve analyses of surrogate biomarkers.

All other aspects of the FOA remain unchanged.

Please direct all inquiries to:

Scientific/Research Contact

Brandy Heckman-Stoddard, Ph.D., M.P.H.
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 2129
Bethesda, MD 20892-7333
Telephone: 301-594-0696
Email: heckmanbm@mail.nih.gov